TCF4 and diffuse large B-cell lymphoma: Likewise, in line with the recently reported high-risk DLBCL cluster ‘A7’ featuring primarily ABC subtype tumors with abundant MYC pathway activation [69], enrichment for gains at 18q21 fostering upregulation of TCF4, a transcription factor known to regulate MYC expression [70], may support rrDLBCL patients as strong candidates for MYC pathway targeting agents (BETi).